IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — Hagens Berman
SAN FRANCISCO, April 27, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to...
Read moreDetails